Literature DB >> 15025034

Intragastric balloon: another option for treatment of obesity and morbid obesity.

S B Doldi1, G Micheletto, M N Perrini, R Rapetti.   

Abstract

BACKGROUND/AIMS: The BioEnterics Intragrastric Balloon (BIB, BioEnterics, Santa Barbara, CA) in association with restricted diet has been used for the treatment of obesity and morbid obesity.
METHODOLOGY: Since March 1998, 349 BIB were placed in 303 obese and morbidly obese patients; 95 patients were male and 208 female; mean age was 41.5 years (19-70); mean weight was 118.8 Kg (67-229); mean BMI was 42 Kg/m2, % excess weight was 62.3% (4.6-216.3). The balloon was inserted and removed endoscopically under general anesthesia. Patients were given a balanced diet of 1000 Kcal/day.
RESULTS: After 4 months of balloon treatment, the mean weight loss was 13.9 Kg and the mean reduction in BMI was 4.8 Kg/m2. Weight loss was greater in male patients. Weight loss was accompanied by an improvement of the diseases associated with obesity, in particular diabetes.
CONCLUSIONS: The best indications for BIB were: morbidly obese (BMI >40) and super-obese patients (BMI >50) in preparation for bariatric operations; obese patients with BMI 35-40 with co-morbidity in preparation for bariatric surgery; obese patients with BMI 30-35 with a chronic disease otherwise unresolved; patients with BMI <30 only in a multidisciplinary approach.

Entities:  

Mesh:

Year:  2004        PMID: 15025034

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  23 in total

1.  Esophageal perforation after gastric balloon extraction.

Authors:  Dan Ruiz; Kelly Vranas; Davida A Robinson; Liberato Salvatore; James W Turner; Talat Addasi
Journal:  Obes Surg       Date:  2008-08-08       Impact factor: 4.129

Review 2.  Evidence-based review of the Bioenterics intragastric balloon for weight loss.

Authors:  Jean-Marc Dumonceau
Journal:  Obes Surg       Date:  2008-06-21       Impact factor: 4.129

3.  Natural orifice transluminal endoscopic gastric bypass performed in a cadaver.

Authors:  Atul K Madan; David S Tichansky; Khurram A Khan
Journal:  Obes Surg       Date:  2008-06-24       Impact factor: 4.129

4.  One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K.

Authors:  J Brooks; E D Srivastava; E M H Mathus-Vliegen
Journal:  Obes Surg       Date:  2014-05       Impact factor: 4.129

Review 5.  Endoscopic treatment of obesity.

Authors:  Agnieszka Swidnicka-Siergiejko; Eugeniusz Wróblewski; Dabrowski Andrzej
Journal:  Can J Gastroenterol       Date:  2011-11       Impact factor: 3.522

6.  Obesity treatment using a Bioenterics intragastric balloon (BIB)--preliminary Croatian results.

Authors:  Marko Nikolic; Gorana Mirosevic; Neven Ljubicic; Marko Boban; Vladimir Supanc; Borka Pezo Nikolic; Vanja Zjacic-Rotkvic; Miroslav Bekavac-Beslin; Petar Gacina
Journal:  Obes Surg       Date:  2011-08       Impact factor: 4.129

Review 7.  Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis.

Authors:  Iñaki Imaz; Carmen Martínez-Cervell; Elvira Elena García-Alvarez; Juan Manuel Sendra-Gutiérrez; Jesús González-Enríquez
Journal:  Obes Surg       Date:  2008-05-06       Impact factor: 4.129

8.  Safety of the Ullorex oral intragastric balloon for the treatment of obesity.

Authors:  Corby K Martin; Drake E Bellanger; Kristina K Rau; Sandra Coulon; Frank L Greenway
Journal:  J Diabetes Sci Technol       Date:  2007-07

Review 9.  Gastric Perforation following Intragastric Balloon Insertion: Combined Endoscopic and Laparoscopic Approach for Management: Case Series and Review of Literature.

Authors:  Bassem M Abou Hussein; Ali A Khammas; Ali M Al Ani; Abeer H Swaleh; Sameer A Al Awadhi; Yousif H El Tayyeb; Alya S Al-Mazrouei; Faisal M Badri
Journal:  Obes Surg       Date:  2016-05       Impact factor: 4.129

10.  BioEnterics intragastric balloon for treatment of morbid obesity in Prader-Willi syndrome: specific risks and benefits.

Authors:  F De Peppo; G Di Giorgio; M Germani; E Ceriati; P Marchetti; C Galli; M G Ubertini; S Spera; G Ferrante; M Cuttini; M Cappa; G Castelli Gattinara; M Rivosecchi; A Crinò
Journal:  Obes Surg       Date:  2008-05-01       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.